Stock listing

Lang & Schwarz:A3E4P8 Syntara Limited Aktie

German listing (Lang & Schwarz) of Syntara Limited · home listing ASX:SNT

Follow Syntara Limited into a list and get an email when it puts out news.

Home listing price · ASX:SNT

$0.014 AUD -0.001 (-3.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ASX:SNT

Past year -53.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.013 – $0.014 AUDNov 20, 2026
Volume
2.38M sharesNov 20, 2026
Market cap
$27.50M AUDAt the close on Nov 20, 2026 · price × 1.96B shares outstanding
52-week range
$0.013 – $0.036 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$32,961 AUDMedian day 715,498 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Syntara Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:SNT · Home$0.014 AUD-0.001 (-3.4%)2,383,516$0.013$0.014$0.013$0.015Close on Nov 20, 2026
Frankfurt:UUDA€0.012 EUR0.000 (0.0%)—€0.012€0.012€0.012€0.012Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:SNT · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.014-0.001-3.4%$0.013$0.014$0.0132,383,516
$0.015+0.001+3.6%$0.014$0.015$0.0141,376,203
$0.014+0.001+3.7%$0.013$0.014$0.0131,562,657
$0.014-0.001-3.6%$0.013$0.014$0.013165,731
$0.0140.0000.0%$0.014$0.014$0.0131,562,461
$0.0140.0000.0%$0.015$0.015$0.0131,656,222
$0.0140.0000.0%$0.015$0.015$0.0142,353,641
$0.014-0.002-12.5%$0.016$0.016$0.0144,583,481
$0.016-0.003-15.8%$0.018$0.018$0.01314,284,984
$0.019+0.001+5.6%$0.019$0.019$0.01950,195
$0.0180.0000.0%$0.018$0.018$0.01884,582
$0.0180.0000.0%$0.019$0.019$0.01842,665
$0.018-0.001-5.3%$0.019$0.019$0.01876,222
$0.019+0.001+2.7%$0.019$0.019$0.01967,794
$0.019-0.001-2.6%$0.019$0.019$0.019107
$0.019+0.001+5.6%$0.019$0.019$0.01915,000
$0.0180.0000.0%$0.018$0.019$0.018105,700
$0.018-0.001-5.3%$0.018$0.019$0.018189,903
$0.0190.0000.0%$0.019$0.019$0.0183,983,702
$0.019-0.001-5.0%$0.020$0.020$0.019726,890
$0.0200.0000.0%$0.019$0.020$0.019243,234
$0.020+0.001+2.6%$0.020$0.020$0.01941,301
$0.020-0.001-2.5%$0.020$0.020$0.019284,084
$0.020+0.001+5.3%$0.020$0.020$0.019280,610
$0.019-0.003-13.6%$0.021$0.021$0.0197,236,833
$0.022-0.002-8.3%$0.024$0.024$0.0216,378,890
$0.024-0.001-4.0%$0.025$0.025$0.024645,400
$0.0250.0000.0%$0.024$0.025$0.0243,758,269
$0.025+0.001+4.2%$0.025$0.025$0.0231,738,773
$0.024-0.001-4.0%$0.026$0.026$0.0243,484,639
$0.025+0.004+19.0%$0.023$0.026$0.0237,936,143
$0.021+0.001+5.0%$0.021$0.022$0.0212,121,486
$0.020-0.002-9.1%$0.021$0.021$0.0202,418,234
$0.022+0.001+4.8%$0.021$0.022$0.021224,409
$0.0210.0000.0%$0.021$0.021$0.02089,584
$0.021-0.001-4.5%$0.022$0.022$0.0202,531,939
$0.0220.0000.0%$0.023$0.023$0.022445,195
$0.022-0.001-4.3%$0.023$0.023$0.0221,170,961
$0.0230.0000.0%$0.023$0.024$0.0213,195,158
$0.023-0.001-4.2%$0.023$0.023$0.02318,568
$0.024+0.001+4.3%$0.023$0.024$0.02354,563
$0.023-0.001-4.2%$0.024$0.024$0.0231,996,423
$0.0240.0000.0%$0.024$0.024$0.023274,526
$0.024+0.001+4.3%$0.024$0.026$0.0236,145,038
$0.0230.0000.0%$0.023$0.024$0.023239,258
$0.0230.0000.0%$0.024$0.024$0.0231,093,495
$0.023-0.002-8.0%$0.025$0.025$0.023357,066
$0.025+0.001+4.2%$0.025$0.026$0.024205,829
$0.024-0.001-4.0%$0.025$0.025$0.024266,733
$0.025+0.001+4.2%$0.024$0.026$0.024752,278
$0.0240.0000.0%$0.024$0.024$0.024942,209
$0.024-0.001-4.0%$0.025$0.025$0.0248,759
$0.0250.0000.0%$0.027$0.027$0.025909,111
$0.025-0.001-3.8%$0.026$0.027$0.0252,447,163
$0.0260.0000.0%$0.027$0.027$0.026272,031
$0.0260.0000.0%$0.026$0.027$0.025414,042
$0.0260.0000.0%$0.026$0.026$0.025859,687
$0.0260.0000.0%$0.026$0.026$0.025254,039
$0.0260.0000.0%$0.026$0.026$0.0262,184,770
$0.026-0.001-3.7%$0.027$0.027$0.026390,803
$0.027+0.002+8.0%$0.025$0.027$0.025419,534
$0.025+0.001+4.2%$0.026$0.026$0.025925,364
$0.024-0.003-11.1%$0.026$0.027$0.0242,496,276
$0.027+0.001+3.8%$0.025$0.027$0.025360,329
$0.026-0.001-1.9%$0.026$0.026$0.025704,106
$0.027-0.001-1.9%$0.026$0.027$0.026784,779
Ticker
Lang & Schwarz:A3E4P8
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

Results of Meeting

Nov 18, 2026

Closed $0.015 (+3.6%) on Nov 19, 2026

CEO Presentation

Nov 18, 2026

Closed $0.015 (+3.6%) on Nov 19, 2026

Chair's Address to Shareholders

Nov 18, 2026

Closed $0.015 (+3.6%) on Nov 19, 2026

Syntara Pauses SNT-9465 Phase 1b Recruitment

Nov 9, 2026

Closed $0.016 (-15.8%) on Nov 10, 2026

All Syntara Limited news

Syntara Limited on 6ix

Sector
Health care
Industry
Biotechnology
News releases
29 in the last 12 months · 139 in all · newest Nov 18, 2026 · oldest 2016
Decks
41 decks · latest Nov 19, 2026

Where Syntara Limited is listed

ListingExchangeCountryCurrency
ASX:SNT · Home listingASXAustraliaAUD
LS Exchange:A3E4P8LS ExchangeGermanyEUR
Lang & Schwarz:A3E4P8 · This pageLang & SchwarzGermanyEUR
Frankfurt:UUDAFrankfurtGermanyEUR
OTC:PMXSFOTCUnited StatesUSD
Dusseldorf:UUDADusseldorfGermanyEUR
Munich:UUDAMunichGermanyEUR
Stuttgart:UUDAStuttgartGermanyEUR

Valuation

EV/sales 2.0× against a median of 15.6×: the lowest of 4 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$13.94M AUD
P/E
Loss
EV/sales
2.0×
EV/EBITDA
Negative EBITDA
Price/book
1.7×
Gross margin
−6.5%
Operating margin
−235.2%
Net margin
−129.8%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Syntara Limited · ASX:SNTUS$18.20MUS$9.23Mn/a2.0×n/a1.7×−129.8%0.0×n/a
Adicet Bio, Inc. · NASDAQ:ACETUS$20.03MUS$5.02Mn/an/an/a0.2×n/a0.1×2.02
IGC Pharma, Inc. · AMEX:IGCUS$19.60MUS$19.19Mn/an/an/a3.0×n/a0.0×1.09
Provectus Biopharmaceuticals, Inc. · OTC:PVCTUS$19.12MUS$18.94Mn/an/an/an/an/an/a-0.21
LeonaBio, Inc. · NASDAQ:LONAUS$19.03M−US$12.82Mn/an/an/a1.2×n/a0.0×1.04
Cocrystal Pharma, Inc. · NASDAQ:COCPUS$18.30MUS$14.69Mn/a33.8×n/a6.8×n/a0.5×1.21
Marker Therapeutics, Inc. · NASDAQ:MRKRUS$18.17MUS$9.13Mn/a4.9×n/a1.7×−461.1%0.0×1.49
Resverlogix Corp. · TSX:RVXUS$18.01MUS$95.55Mn/an/an/an/an/an/a0.26
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.76MUS$15.67Mn/an/an/a13.4×n/a1.1×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Median of the othersUS$18.24MUS$14.87M15.6×2.8×−319.8%0.0×1.09

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
0.10 AUD · Analysts' mean
EPS, year to Jun 2027
-0.005 · 1 analyst

Team and board

Officers

OfficerRole
Gary PhillipsChief Executive Officer
Tim LuscombeChief Financial Officer & Company Secretary
Dieter HamprechtHead of Chemistry
Jana BaskarChief Medical Officer
Kristen MorganHead of Medical and Regulatory Affairs
Wolfgang JarolimekHead of Drug Discovery

Board

DirectorRole
Kathleen MettersIndependent Chair
Hashan De SilvaNon-Executive Director
Simon GreenNon-Executive Director

Events

QuarterResultsShare move
Quarter to Mar 31, 2026Apr 28, 2026−12.5%
Quarter to Sep 30, 2025Nov 28, 2025−5.9%
Q4 2025Aug 28, 2025+1.9%
Quarter to Mar 31, 2025May 30, 2025−5.8%
Q2 2025Feb 26, 2025+3.8%
Quarter to Sep 30, 2024Nov 29, 2024+20.0%
Q4 2024Aug 30, 2024−2.9%
Quarter to Mar 31, 2024Apr 29, 2024−5.9%
Q2 2024Jan 30, 2024+11.8%
Quarter to Sep 30, 2023Oct 30, 2023−3.0%
All 20 quarters
QuarterResultsShare move
Q4 2023Jul 20, 2023−3.7%
Q2 2023Jan 30, 2023+1.7%
Quarter to Sep 30, 2022Oct 30, 2022+1.6%
Q4 2022Aug 30, 20220.0%
Quarter to Mar 31, 2022Apr 28, 2022−4.0%
Q2 2022Jan 30, 2022+1.0%
Quarter to Sep 30, 2021Oct 27, 2021+8.7%
Q4 2021Jul 28, 20210.0%
Quarter to Mar 31, 2021Jun 4, 2021−1.2%
Q2 2021Jan 28, 2021−2.2%

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (November 2026)Shareholder meeting17 slidesNov 19, 2026
Shareholder Meeting (November 2026)Shareholder meeting17 slidesNov 19, 2026
Canaccord Drug & Device Conference 2026Conference20 slidesOct 13, 2026
Corporate Update (July 2026)Corporate update12 slidesJul 28, 2026
Investor Presentation (July 2026)Investor deck31 slidesJul 27, 2026
Technical Presentation (July 2026)Technical11 slidesJul 6, 2026
Investor Presentation (June 2026)Investor deck20 slidesJun 1, 2026
Investor Presentation (April 2026)Investor deck46 slidesApr 29, 2026
NWR Virtual Healthcare Conference (March 2026)Conference29 slidesMar 25, 2026
Euroz Hartleys 2026 Healthcare ForumConference15 slidesFeb 5, 2026
All 41 decks
DeckKindSlidesDate
Investor Presentation (February 2026)Investor deck9 slidesFeb 3, 2026
Hong Kong Ignite Investment Summit (October 2025)Conference17 slidesOct 15, 2025
Corporate Update (September 2025)Corporate update18 slidesSep 30, 2025
E&P 4th Annual Small Cap Healthcare Conference (September 2025)Conference18 slidesSep 9, 2025
Investor Presentation (August 2025)Investor deck19 slidesAug 19, 2025
Corporate Update (August 2025)Corporate update7 slidesAug 1, 2025
European Hematology Association Congress 2025Conference21 slidesJun 13, 2025
Non-Deal Roadshow (May 2025)Roadshow24 slidesMay 7, 2025
Q1 2025 Earnings PresentationEarnings11 slidesMay 1, 2025
Euroz Hartleys Healthcare Forum (February 2025)Conference22 slidesFeb 4, 2025
Investor Presentation (December 2024)Investor deck40 slidesDec 12, 2024
Technical Presentation (December 2024)Technical20 slidesDec 10, 2024
Technical Presentation (December 2024)Technical20 slidesDec 10, 2024
Technical Presentation (December 2024)Technical14 slidesDec 9, 2024
Shareholder Meeting (November 2024)Shareholder meeting31 slidesNov 28, 2024
Q3 2024 Earnings PresentationEarnings13 slidesOct 30, 2024
Investor Presentation (October 2024)Investor deck15 slidesOct 16, 2024
Investor Presentation (July 2024)Investor deck43 slidesJul 30, 2024
Investor Presentation (July 2024)Investor deck20 slidesJul 1, 2024
Non-Deal Roadshow (April 2024)Roadshow20 slidesApr 30, 2024
Q1 2024 Earnings PresentationEarnings10 slidesApr 30, 2024
NWR Virtual Healthcare Conference (March 2024)Conference19 slidesMar 20, 2024
Investor Presentation (March 2024)Investor deck21 slidesMar 6, 2024
Euroz Hartleys 2024 Healthcare ForumConference18 slidesFeb 6, 2024
Q4 2023 Earnings PresentationEarnings9 slidesFeb 1, 2024
Investor Presentation (December 2023)Investor deck44 slidesDec 19, 2023
Shareholder Meeting (November 2023)Shareholder meeting13 slidesNov 28, 2023
Earnings Presentation (October 2023)Earnings11 slidesOctober 2023
Investor Presentation (October 2022)Investor deck43 slidesOct 19, 2022
Shareholder Meeting (November 2018)Shareholder meeting36 slidesNov 22, 2018
Investor Presentation (August 2018)Investor deck28 slidesAug 6, 2018

Open Decks

Financings

RaiseDateIn US dollars
Share purchase plan of new fully paid ordinary shares
Closed: A$840,000 raised · A$0.027 a share
Use of proceeds: Cash runway to Q3 2027: clinical trial readouts and licensing, Phase 2b MF study preparation, patent suite, offer costs
Jun 10, 2026US$589,447
Private placement of new fully paid ordinary shares
Announced: A$8M · A$0.027 a share · Canaccord Genuity (Australia) Limited +1
Dealers: Canaccord Genuity (Australia) Limited (co-lead), Euroz Hartleys Limited (co-lead)
Use of proceeds: Five clinical trial readouts in 2026, licensing discussions, Phase 2b myelofibrosis study preparation, patent suite and offer costs; runway to Q3 2027
Apr 29, 2026US$5.71M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue6.93M7.30M5.43M5.76M5.76M7.43M23.6M7.03M5.68M49.4M
Cost of revenue7.38M223.0K8.30M2.71M9.95M15.4M16.1M15.9M1.77M
Gross profit-450.0K-223.0K3.06M3.06M7.43M7.21M-9.09M-10.2M47.3M
Research and development7.38M8.71M7.22M4.77M6.34M8.66M
Selling, general and administrative1.51M9.00M17.3M15.5M14.1M14.9M14.5M15.5M15.1M14.2M
Operating income-16.3M-22.1M-14.1M-18.7M-19.8M-19.9M-4.40M-20.9M-24.5M16.9M
Depreciation and amortization146.0K223.0K232.0K232.0K1.85M3.24M3.15M3.24M2.62M3.11M
EBITDA-16.2M-21.9M-13.8M-18.5M-18.0M-16.7M-1.25M-17.6M-21.9M20.0M
Interest expense10.0K30.0K386.0K223.0K223.0K369.0K238.0K563.0K623.0K
Income before tax-9.61M-12.3M-13.7M-18.2M-18.7M-1.94M-3.12M-19.1M-26.0M6.26M
Income tax-4.73M-5.61M-4.56M-5.25M-4.90M-148.0K-5.16M-8.00K-169.0K
Net income-8.99M-7.92M-15.1M-11.4M-1.94M-2.97M-13.9M-20.1M6.43M-18.3M
Earnings per share, basic-0.01-0.01-0.01-0.02-0.00-0.01-0.04-0.050.02-0.06

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents13.6M15.1M3.52M9.23M8.94M18.7M14.8M31.1M31.1M21.5M
Short-term investments2.77M6.00M
Receivables19.0K5.66M7.48M7.64M2.74M6.94M7.19M2.39M4.43M
Inventory1.64M2.34M3.64M2.63M2.12M2.40M2.57M
Current assets18.8M21.0M9.77M18.7M19.2M25.3M24.5M40.6M36.0M28.6M
Property, plant and equipment180.0K383.0K1.84M3.21M
Total assets19.1M21.4M10.4M24.0M25.2M33.6M35.4M52.7M50.1M45.4M
Accounts payable1.23M2.52M614.0K1.58M615.0K1.24M1.76M2.20M2.13M3.32M
Current liabilities2.86M5.34M5.45M8.03M6.10M7.89M6.83M8.11M8.24M10.5M
Total debt84.0K2.04M4.29M6.32M8.15M7.17M8.27M9.25M
Total liabilities2.92M5.42M5.70M14.5M14.4M30.7M34.0M37.9M39.0M41.9M
Shareholders' equity16.2M16.0M4.68M9.56M10.8M2.85M1.43M14.8M11.1M3.52M
Shares outstanding1.67B1.47B1.19B655.6M562.9M407.3M394.7M381.4M319.7M318.5M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-9.78M-11.1M-7.28M-16.3M3.07M-13.3M-19.8M12.2M-15.3M
Capital spending-2.00K0-7.00K-138.0K-307.0K-647.0K-574.0K-981.0K-840.0K-723.0K
Free cash flow-9.78M-11.1M-14.5M-7.42M-16.6M2.42M-13.9M-20.8M11.4M-16.0M
Cash from investing-2.00K4.18M-131.0K-306.0K-644.0K-574.0K-981.0K-884.0K-723.0K
Cash from financing8.26M18.5M7.20M6.98M6.63M1.52M-2.50M20.8M-1.75M-1.72M
Dividends paid-2.25M-2.38M-2.31M
Share buybacks-494.0K-1.35M-678.0K-678.0K-741.0K-301.0K0
Change in cash-1.51M11.6M-5.80M293.0K-9.78M3.95M-16.4M51.0K9.57M-17.7M

Open Financials

Filings

FilingDateTypeFiled with
Results of MeetingNov 18, 2026Meeting outcomeASX
CEO PresentationNov 18, 2026Other filingsASX
Chair's Address to ShareholdersNov 18, 2026Other filingsASX
Syntara Pauses SNT-9465 Phase 1b RecruitmentNov 9, 2026Operations updateASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 29, 2026Quarterly reportASX
Notice of Annual General Meeting/Proxy FormOct 19, 2026Meeting noticeASX
Investor Presentation Canaccord Drug & Device ConferenceOct 12, 2026Other filingsASX
Further significant results from SNT-4728 iRBD Phase 2 trialOct 6, 2026Other filingsASX
Notification regarding unquoted securities - SNTOct 4, 2026Other filingsASX
All 139 filings
FilingDateTypeFiled with
Notification regarding unquoted securities - SNTOct 4, 2026Other filingsASX
Syntara expands SNT-9465 skin scarring studySep 30, 2026Operations updateASX
Syntara receives A$4.7m R&D Tax IncentiveSep 20, 2026Other filingsASX
Application for quotation of securities - SNTSep 14, 2026FinancingASX
Notification of 2026 AGM DateSep 14, 2026Meeting noticeASX
Appendix 4E and Annual ReportAug 27, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementAug 27, 2026Other filingsASX
Investor Update Webinar PresentationJul 27, 2026Other filingsASX
Encouraging SNT-4728 Phase 2 iRBD resultsJul 5, 2026Other filingsASX
Results of Share Purchase PlanJun 10, 2026ResultsASX
Share Purchase Plan Offer BookletMay 13, 2026FinancingASX
$8m placement and share purchase planApr 29, 2026FinancingASX
Continuation of trading haltApr 28, 2026Trading halt or suspensionASX
Positive FDA feedback for Amsulostat P2b trialApr 27, 2026Operations updateASX
Half Year Report and Appendix 4DFeb 25, 2026Interim reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 28, 2026Quarterly reportASX
Amsulostat and Garvan in MRFF funded pancreatic trialJan 20, 2026Operations updateASX
SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruitedJan 7, 2026Operations updateASX
Skin scarring program to progress on positive Phase1a resultNov 25, 2025Other filingsASX
Quarterly Shareholder Report and Appendix 4COct 27, 2025Quarterly reportASX
Positive top-line Phase 2a data confirms competitive profileSep 29, 2025ResultsASX
Preliminary Final ReportAug 28, 2025Annual reportASX
Guidance from FDA on amsulostat clinical progressionAug 11, 2025GuidanceASX
Reinstatement to QuotationAug 4, 2025Trading halt or suspensionASX
Suspension from QuotationJul 31, 2025Trading halt or suspensionASX
Quarterly Appendix 4C Cash Flow ReportJul 31, 2025Quarterly reportASX
Quarterly Shareholder ReportJul 30, 2025Quarterly reportASX
New positive interim data in Phase 2 study of SNT-5505Jun 12, 2025Other filingsASX
SNT-5505 awarded US FDA Fast Track designationJun 9, 2025Operations updateASX
Quarterly Activities ReportApr 29, 2025Quarterly reportASX
Acceleration of skin scarring programMar 17, 2025Other filingsASX
Equity Raising PresentationDec 11, 2024Other filingsASX
PlacementDec 11, 2024FinancingASX
Interim data in Phase 2 study of SNT-5505 in myelofibrosisDec 10, 2024Operations updateASX
Presentation: Phase 2 study of SNT-5505 in myelofibrosisDec 10, 2024Other filingsASX
Trading HaltDec 9, 2024Trading halt or suspensionASX
Response to ASX Price QueryDec 4, 2024Explanation requestASX
Pause in TradingDec 3, 2024Trading halt or suspensionASX
Appendix 4E and Annual Report to shareholdersAug 30, 2024Annual reportASX
Half Yearly Report and AccountsFeb 29, 2024Interim reportASX
PXS Company Restructure Sale of Mannitol BusinessOct 2, 2023Other filingsASX
PXS to Receive Prepayment of 2023 Research Tax IncentiveAug 7, 2023Other filingsASX
Final Set of Interim Data from PXS-5505 in MyelofibrosisJul 12, 2023Other filingsASX
PXS Announces Encouraging Results from Phase 1c Scar StudyMay 23, 2023Other filingsASX
After FDA Review PXS Accelerates Plans for Combination StudyApr 11, 2023Other filingsASX
PXS announces positive interim data from myelofibrosis trialOct 18, 2022Other filingsASX
Investor PresentationOct 18, 2022Other filingsASX
PXS Releases Promising Interim Data from Skin Scarring StudySep 25, 2022Other filingsASX
PXS to Receive Stg2.9m from Parkinsons UK for New TrialAug 31, 2022Other filingsASX
Aptar Pharma Pays PXS Us$5m to Acquire Orbital TechnologyAug 4, 2022Acquisition or disposalASX
Clarification AnnouncementMay 13, 2022Other filingsASX
Appendix 4C Quarterly Cash Flow ReportApr 28, 2022Quarterly reportASX
Response to ASX Aware QueryJan 10, 2022Explanation requestASX
PXS Collaborators Receive Government Grants of $1.4mJan 5, 2022Other filingsASX
Share Purchase PlanDec 20, 2021FinancingASX
Security Purchase PlanNov 24, 2021Other filingsASX
FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer StudyNov 8, 2021Other filingsASX
Appendix 4C Cash Flow ReportOct 27, 2021Quarterly reportASX
PXS Doses First Patient in Phase 2 Bone Marrow Cancer TrialOct 13, 2021Other filingsASX
PXS Cleared to Progress to Phase 2 Bone Marrow Cancer TrialOct 4, 2021Other filingsASX
Pharmaxis Treatment to Prevent Wound and Burns Scars ClearsAug 30, 2021Other filingsASX
PXS Grants Exclusive Option to Develop High Payload InhalerAug 16, 2021Other filingsASX
PXS Drug Decreases Tumour Burden in Liver Cancer ModelAug 4, 2021Other filingsASX
PXS Sells Australian Distribution Rights for A$2mJun 30, 2021Other filingsASX
PXS Announces First Results in Bone Marrow Cancer TrialJun 29, 2021Other filingsASX
Quarterly Activity ReportApr 30, 2021Other filingsASX
Appendix 4C - quarterlyApr 30, 2021Quarterly reportASX
Sale of Russian Distribution RightsApr 13, 2021Other filingsASX
First Patient Enrolled - Clinical Trial for Cancer TreatmentFeb 21, 2021Other filingsASX
Pharmaxis Exports CF Drug to US - US$3 Million MilestoneFeb 8, 2021Other filingsASX
Quarterly Activity Report - December 2020Jan 28, 2021Other filingsASX
Pharmaxis Receives US$7m milestone from ChiesiDec 29, 2020Other filingsASX
Pharmaxis Prioritises Clinical Program on MyelofibrosisNov 1, 2020Other filingsASX
September Quarter 2020 Activity ReportOct 29, 2020Other filingsASX
Boehringer Ingelheim discontinues development of BI 1467335Sep 6, 2020Other filingsASX
Pharmaxis Awarded $1M Australian Government GrantSep 2, 2020Other filingsASX
FDA Gives Green Light to Start Myelofibrosis Phase 2 StudyAug 19, 2020Other filingsASX
US$7 million Bronchitol Launch Milestone Brought ForwardAug 4, 2020Other filingsASX
Fourth Quarter Activity ReportJul 30, 2020Other filingsASX
Pharmaxis Quarterly Shareholder Update - March 2020Apr 29, 2020Other filingsASX
PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020Apr 27, 2020Other filingsASX
Quarterly Shareholder Update - December 2019Jan 30, 2020Other filingsASX
Pharmaxis Business Plan UpdateDec 17, 2019Other filingsASX
Quarterly Shareholder Update - September 2019Oct 30, 2019Other filingsASX
FDA Provides Guidance on Bronchitol Approval StepsOct 27, 2019GuidanceASX
Pharmaxis Receives $6.2m R&D Tax IncentiveOct 16, 2019Other filingsASX
Quarterly Shareholder Update - June 2019Jul 25, 2019Other filingsASX
Pathway to US Bronchitol Approval Clarified in FDA ResponseJun 19, 2019Other filingsASX
US Advisory Committee Positive Recommendation on BronchitolMay 8, 2019Other filingsASX
Quarterly Shareholder Update - March 2019Apr 29, 2019Other filingsASX
Pharmaxis Commences Phase 1 LOX Clinical TrialFeb 21, 2019Other filingsASX
Quarterly Shareholder Update - December 2018Jan 29, 2019Other filingsASX
Pharmaxis Announces LOXL2 Program Phase 2 ReadyJan 16, 2019Other filingsASX
PHARMAXIS ANNOUNCES RESUBMISSION OF BRONCHITOL NDA IN USADec 19, 2018Other filingsASX
Pharmaxis Announces First Relaunch Sales of Aridol in USADec 12, 2018Other filingsASX
Pharmaxis AGM - CEO PresentationNov 22, 2018Other filingsASX
LOX Inhibitor Program for Pancreatic Cancer Phase 1 ReadyNov 19, 2018Other filingsASX
Pharmaxis Releases Positive Results of Phase 1 Clinical TriaNov 14, 2018Other filingsASX
Positive Phase 1 Results of Phase 1 Study - LOXL2 InhibitorOct 10, 2018Other filingsASX
FDA Factory Approval and Relaunch of Aridol in US MarketAug 14, 2018Other filingsASX
Capital Raising PresentationAug 6, 2018FinancingASX
Trading Halt Announcement - System UpgradeAug 5, 2018Trading halt or suspensionASX
Quarterly Shareholder Update - June 2018Jul 26, 2018Other filingsASX
LOXL2 Program Attracts Strong Partner Interest at BIO18Jun 13, 2018Other filingsASX
Quarterly Shareholder Update - March 2018Apr 30, 2018Other filingsASX
Pharmaxis Earns A$15 Million Milestone PaymentJan 10, 2018Other filingsASX
New Australian PBS Listing for BrocnhitolJan 1, 2018Other filingsASX
Pharmaxis Acquires Control, Increases Stake in LOXL2 ProgramDec 13, 2017Acquisition or disposalASX
Boehringer Initiating Phase 2a Study Diabetic RetinopathySep 7, 2017Other filingsASX
Antifibrotic LOXL2 Program Clears Preclinical DevelopmentSep 5, 2017Other filingsASX
Boehringer Ingelheim Initiates Phase IIa Study in NASHAug 24, 2017Other filingsASX
Positive Recommendation for Broader Bronchitol Access in AusAug 18, 2017Other filingsASX
Preliminary Final Report June 2017Aug 10, 2017ResultsASX
Appendix 4C - quarterly June 2017Jul 28, 2017Quarterly reportASX
Pharmaxis Announces Results of Pivotal CF Clinical TrialJun 12, 2017Other filingsASX
Pharmaxis Set to Generate Further Euro 10m Milestone PaymentMay 14, 2017Other filingsASX
Pharmaxis Appoints Chiesi as Bronchitol Distributor in ItalyMay 8, 2017Other filingsASX
Appendix 4C - quarterly cash flowApr 18, 2017Quarterly reportASX
Quarterly Shareholder Update March 2017Apr 17, 2017Other filingsASX
Synairgen Collaboration ProgressMar 12, 2017Other filingsASX
Chairmans Address to ShareholdersNov 29, 2016Other filingsASX
Research Collaboration with Woolcock InstituteNov 15, 2016Other filingsASX
S&P DJ Indicies Announces March Quarterly RebalanceNov 7, 2016Other filingsASX
Pharmaxis Announces Russian Approval for BronchitolSep 26, 2016Other filingsASX
Pharmaxis Completes Recruitment of CF Clinical Trial for USJul 14, 2016Other filingsASX
Appendix 4C - quarterly March 2016Apr 14, 2016Quarterly reportASX
US FDA Accepts Bronchitol New Drug Application for ReviewMar 30, 2016Other filingsASX
Quarterly Share Update - December 2015Feb 11, 2016Other filingsASX
Bronchitol Paediatric CF Trial Reports Postive ResultsFeb 10, 2016Other filingsASX

Open Filings

Cap table

Built by 6ix from Syntara Limited’s releases · as of Jun 10, 2026

Common shares
1,964,519,275
Fully diluted
1,964,519,275

Fully diluted

LineShares
Common shares1,964,519,275

Share count over time

CountShares
Nov 22, 20261,964,519,275

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Dieter HamprechtHead of Chemistry · Since at least Nov 5, 2026
Gary PhillipsChief Executive Officer · Since at least Jul 28, 2026
Hashan De SilvaNon-Executive Director · Since at least Nov 5, 2026
Jana BaskarChief Medical Officer · Since at least Nov 5, 2026
Kathleen MettersIndependent Chair · Since at least Nov 5, 2026
Kristen MorganHead of Medical and Regulatory Affairs · Since at least Nov 5, 2026
Simon GreenNon-Executive Director · Since at least Nov 5, 2026
Tim LuscombeChief Financial Officer & Company Secretary · Since at least Nov 4, 2026
Wolfgang JarolimekHead of Drug Discovery · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Syntara Limited.